A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2021-01-25
Target enrollment:
Participant gender:
Summary
An open-label, dose-escalation study to assess the safety and pharmacokinetics (PK), to
determine the dose limiting toxicity (DLT) and the recommended Phase 2 dose (RPTD), and to
assess the preliminary efficacy of alvocidib with venetoclax when co-administered in
participants with relapsed or refractory (R/R) acute myeloid leukemia (AML).
Phase:
Phase 1
Details
Lead Sponsor:
AbbVie
Collaborators:
Sumitomo Dainippon Pharma Oncology, Inc Tolero Pharmaceuticals, Inc.